AbbVie to Build $1.4 Billion AI-Integrated Manufacturing Campus in North Carolina
AbbVie has selected North Carolina as the site for a new $1.4 billion manufacturing campus that will integrate artificial intelligence with advanced production and laboratory technologies to support its immunology, neuroscience, and oncology medicine lines. No timeline for completion was announced.
The investment reflects both the scale of AbbVie’s pipeline ambitions and a broader pharmaceutical industry trend toward AI-assisted manufacturing—applying machine learning to process optimization, quality control, and yield prediction in ways that reduce variability and regulatory risk. North Carolina’s selection continues its emergence as a life sciences manufacturing hub, following years of investment by major pharmaceutical and biotech firms drawn by workforce infrastructure, university partnerships, and competitive incentive packages. For AbbVie specifically, expanding domestic manufacturing capacity carries strategic weight as trade policy uncertainty continues to make offshored production a liability.